Aim: To investigate multiple risk factor target attainment in adults with diabetes mellitus (DM) for atherosclerotic cardiovascular disease (ASCVD) prevention and the predictors of such attainment in a contemporary DM registry.
| INTRODUCTION
The prevalence of diabetes mellitus (DM) continues to grow rapidly and is associated with substantial increases in risk of coronary heart disease (CHD), heart failure and stroke. 1 There has been great interest in strategies for preventing cardiovascular disease (CVD) in people with DM. Guidelines for the management of DM have highlighted the control of modifiable risk factors for the primary prevention of CVD, 1 including control of glycated haemoglobin (HbA1c), blood pressure (BP) and low density lipoprotein (LDL) cholesterol. 2 However, US national survey data have shown that only a quarter of people with DM achieve targets for HbA1c < 53 mmol/L (< 7%), LDL cholesterol < 2.6 mmol/L (100 mg/dL) and BP < 130/80 mmHg. 3 There has been a focus, therefore, on multifactorial risk factors to improve CVD outcomes, and studies have suggested that patients with DM who have achieved multiple risk factor targets have >50% lower risk of atherosclerotic CVD (ASCVD). 4, 5 Although significant improvement in risk factor control has been noted over the last decade, 3 been developed. The DCR is a real-world, quality-oriented registry covering the spectrum from primary to specialty outpatient care in the United States, thereby providing sufficient multidisciplinary data for clinical practice evaluation. 6 The aim of the present study was to identify multiple risk factor target attainment for ASCVD prevention and its predictors in this contemporary DM registry.
2 | METHODS
| Data collection
The DCR is the first real-world United States-based registry of patients with DM seen in primary care, endocrinology, cardiology and multispecialty practices. This prospective registry was initiated in 2014 and practices were invited to participate through the DCR website at www.thediabetesregistry.org and through partner societies.
System integration software was used to extract relevant data elements from participating electronic health records and a standardized procedure of data quality checks was applied to identify any implausible data. Further information about the design of the registry has been previously published. 6 
| Sample selection

| Definition of target control
According to ADA guidelines for recommended levels of each risk factor, we defined participants at target control as follows: (a) HbA1c level < 53 mmol/mol (7%) or < 64 mmol/mol (8%) if with known ASCVD; (b) LDL cholesterol < 2.6 mmol/L (100 mg/dL) or < 
| Statistical analysis
The proportions of participants at target control for each risk factor were calculated and compared using the chi-squared test of proportions between sex and ethnic groups and between those with and without prior Figure 1 ). Among ethnic groups, white patients had the highest target control rates for Multiple logistic regression models identified increased age, male gender, white race, and high/middle socio-economic status to be independently associated with composite risk factor control (HbA1c, LDL cholesterol, non-smoking status and BP <140/90 mmHg). Patients aged ≥65 years were nearly twice as likely to be at composite targets than patients aged <55 years. Men and white patients were 31% and 38%, respectively, more likely to be at composite risk factor target than women and non-white patients (P < 0.001). Higher socio-economic status (middle to high household income) was associated with a 14% to 44% greater likelihood of composite risk factor control (P < 0.001).
Depression was associated with a 10% lower likelihood of control (P = 0.01). Results were similar when the more strict BP target of <130/80 mmHg was used (Table 2 ).
| DISCUSSION
The present study focused on evaluation of real-world data from the first collaborative DM registry to determine the prevalence of CVD risk factor control among US adults with DM. We showed that, overall, only The value of composite risk factor control is well documented.
A decade ago, beginning with the Steno-2 clinical trial showed among patients randomly assigned to intensive versus conventional therapy, and who had non-smoking status (37% and 13% met three or four criteria, respectively) had 40% lower risks for both all-cause and cardiovascular mortality, along with 27% lower risks for CHD and 37% lower risks for stroke. 13 Most recently, in a report from 271 174 patients in the Swedish National Diabetes Register, the group that was at target with regard to five major risk factors (HbA1c, LDL cholesterol, BP, albuminuria and smoking) was at the same risk of all-cause mortality, myocardial infarction and stroke as a matched control group; there was only an excess risk of hospitalization for heart failure. non-smoking status. *P < 0.05; **P < 0.01; ***P < 0.001.
to 2010 in the US
for these three factors) could be a reflection of the patients in the DCR not being fully representative of US adults with DM, because inclusion in the DCR implies that patients have attended one or more clinic visits, and are potentially sicker and have more comorbidities (nearly 70% with known ASCVD) than free-living adults with DM in the community. However, if the more conservative BP target (<140/90 mmHg) included in the guidelines at the time of DCR, was used, the composite target achievement rate would be closer to that of our earlier report, at 25.3%.
We also used a stricter LDL cholesterol target of < 1.8 mmol/L (70 mg/ dL) but a looser HbA1c target of < 64 mmol/mol (8%) for those with ASCVD. While we did not show differences in target control rates for patients with versus patients without prior CVD, others have noted high risk status to be associated with poorer achievement of targets for BP, lipids and obesity. 15 Also, in a large multicentre survey of 4056 adults with DM in a primary care setting in Beijing, China, only 11% were noted to be at goals for LDL cholesterol, BP and fasting glucose, 16 which is not substantially different from the 53 mmol/mol (7%) we reported in our earlier pooled cohort of US patients with DM.
5
The somewhat poorer risk factor control we demonstrate in women compared to men with DM is concerning, given that the presence of DM attenuates the pre-menopausal female advantage generally noted for cardiovascular risk. 17 In fact, DM confers a higher relative risk of CHD mortality in women than in men. 18, 19 Results from a study in 30 000 patients with DM showed that women with HbA1c levels ≥64 mmol/mol (8%) had a significantly elevated risk of stroke, whereas men did not show this excess risk. 20 A gender disparity in the intensity of CV risk reduction, attributed to worse HbA1c control, less aspirin use, worse BP control and a lower frequency of lipid-lowering therapy, has also been noted in women. 21 We also found that only 18% (10% if the lower BP target is used)
of African-American patients achieved target composite risk factor control, possibly explaining their excess ASCVD risk. Although the prevalence of CHD and stroke among African-American people with DM is lower than in white people with DM (33.0% vs. 33.9%), 22 cardiovascular mortality rates are higher in African-American than in other racial subgroups. This is highlighted by the higher mortality rates observed in African-American versus white patients with DM after myocardial infarction. 23 Among black people with DM, a consistently higher prevalence of CHD/stroke in women compared with men is shown. We found that African-American patients had lower target control for every risk factor than both white and other racial groups.
In addition to gender and ethnic factors, we also showed that lower socio-economic status and depression were associated with poorer composite ASCVD risk control. Socio-economic status is a significant determinant of health associated with CHD. 24 People with DM are reported to experience significantly higher rates of depression than their age-and gender-matched counterparts. 25 People with depression are more likely to develop ASCVD and also have a higher mortality rate than the general population. One study among diabetic veterans showed that those with both DM and depression had an 82% increased risk of new-onset myocardial infarction compared to a 30% increased risk among patients with only type 2 DM or only depression. 26 Depression in patients with DM is also associated with poor self-management and treatment adherence, and an increased risk of DM complications, 27 which is consistent with our findings.
An important strength of the present study is that we used real-world data, from both primary care and specialty practices nationwide, to examine to what extent ASCVD risk factors were under control among patients with DM. The DCR is filling the gap between evidence-based guidelines and practical application by measuring adherence to guidelines and quantifying clinical performance to achieve the goal of health promotion. A limitation of the DCR data is the fact that important minority groups in the United States are under-represented, with white people making up the majority (>85%) of the data collected, emphasizing the need to be more inclusive moving forward with these registry efforts. Another limitation is that the DCR is more enriched in cardiology practices and may not be fully representative of all patients with DM in the country; therefore, estimates generated from the DCR may be more reflective of higher-risk patients. In fact, nearly 70% of our patients had known ASCVD. In addition, collection of such registry data from electronic medical records systems at hundreds of practices can be challenging, as sites do not systematically and consistently collect all variables of interest, leaving a significant percentage of individuals not having the required data to be included in the study.
Another limitation is that, because we only included a fraction of the people in the total registry (those who had complete risk factor information) in the present study, there were some minor (although statistically significant) differences between the patient sample included in the pre- In summary, in our US registry of patients with DM, only one in five adults were achieving comprehensive risk factor control (and fewer than one in six if the stricter BP criterion was used), and women and black patients were especially less likely to achieve this control.
Improved multifactorial interventions, focused both on lifestyle management and evidence-based therapies to achieve all targets, will be necessary to optimize the prevention of CVD. Importantly, our results point to the need for comprehensive and multidisciplinary DM care programmes, team-based care and systems-based approaches, such as use of population quality-focused dashboards, given the significant gaps in care we have identified. 
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